Edwards Lifesciences EW Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Europe | $1.62B+6.6% | $1.52B+4.5% | $1.45B+4.9% | $1.38B+3.4% | $1.34B+1.2% | |
| Japan | $363.5M+2.5% | $354.7M+0.5% | $353.1M+2.5% | $344.4M+2.6% | $335.6M-1.2% | |
| Rest of World | $679.9M+4.2% | $652.3M+3.5% | $630.1M+3.1% | $611.1M+4.2% | $586.4M+2.5% | |
| United States | $3.64B+2.8% | $3.54B+2.7% | $3.45B+3.1% | $3.35B+2.6% | $3.26B+1.8% | |
| Total other segment items by Business | ||||||
| Europe | $116.4M+75.8% | $66.2M+61.5% | $41M+143% | $16.9M+576% | $2.5M-83.2% | |
| Japan | -$11.4M-14.0% | -$10M-38.9% | -$7.2M+17.2% | -$8.7M+28.1% | -$12.1M-77.9% | |
| Rest of World | -$24.7M+6.4% | -$26.4M-3.5% | -$25.5M-8.5% | -$23.5M-26.3% | -$18.6M-77.1% | |
| United States | $2.7M+8.0% | $2.5M+8.7% | $2.3M+4.5% | $2.2M-4.3% | $2.3M-4.2% | |
| Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest by Business | ||||||
| Europe | $837M+5.1% | $796.2M+0.8% | $789.9M+3.9% | $760.6M+2.4% | $742.7M+2.4% | |
| Japan | $242.5M+3.7% | $233.8M-0.3% | $234.5M+2.4% | $229.1M+2.5% | $223.6M+4.8% | |
| Rest of World | $310.7M+4.1% | $298.5M-1.3% | $302.5M+5.1% | $287.7M+9.2% | $263.4M+8.4% | |
| United States | $2.4B+2.2% | $2.35B+2.7% | $2.28B+2.2% | $2.24B+2.0% | $2.19B+1.5% | |
| Selling, general, and administrative expenses by Business | ||||||
| Europe | $313.4M-0.5% | $315M+7.5% | $292.9M+1.7% | $287.9M+1.2% | $284.6M+0.7% | |
| Japan | $78M-0.6% | $78.5M+5.2% | $74.6M+0.3% | $74.4M-1.5% | $75.5M-11.3% | |
| Rest of World | $215.5M+2.8% | $209.6M+10.2% | $190.2M+3.5% | $183.8M+0.9% | $182.1M+0.4% | |
| United States | $596.2M+3.6% | $575.3M+5.0% | $547.9M+2.6% | $533.9M+3.5% | $516M+3.6% | |
| Cost of Sales by Business | ||||||
| Europe | $351.5M+3.4% | $340.1M+3.8% | $327.8M+3.0% | $318.1M+3.4% | $307.7M+2.9% | |
| Japan | $54.4M+3.8% | $52.4M+2.3% | $51.2M+3.2% | $49.6M+2.1% | $48.6M+1.0% | |
| Rest of World | $178.4M+4.6% | $170.6M+4.7% | $162.9M-0.1% | $163.1M+2.3% | $159.5M+0.9% | |
| United States | $646.3M+4.2% | $620.3M+0.9% | $614.5M+7.1% | $574M+3.8% | $552.9M+1.2% | |
| Net Sales by Product | ||||||
| Transcatheter Aortic Valve Replacement | $4.64B+3.4% | $4.49B+2.8% | $4.36B+3.0% | $4.24B+2.2% | $4.14B+0.9% | |
| Transcatheter Mitral and Tricuspid Therapies | $610.5M+10.9% | $550.6M+10.1% | $500M+12.1% | $445.9M+13.1% | $394.4M+12.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Edwards Lifesciences break its business down?
- Edwards Lifesciences (EW) reports net sales by business across 4 parts — Europe, Japan, Rest of World and United States. Each is extracted from the segment footnotes and tracked over time.
- Where does Edwards Lifesciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Edwards Lifesciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
